A truncated Ah receptor blocks the hypoxia and estrogen receptor signaling pathways: A viable approach for breast cancer treatment

Molecular Pharmaceutics

Volumn 3, Issue 6, 2006, Pages 695-703

  Jensen, Kyle A ^a   Luu, Tony C ^a   Chan, William K ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Ah receptor; Arnt; Estrogen receptor; GREB1; HIF 1 ; Protein drugs

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; ESTROGEN RECEPTOR; FRUCTOSE BISPHOSPHATE ALDOLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LACTATE DEHYDROGENASE; LUCIFERASE; MYC PROTEIN; PROTEIN GREB1; PROTEIN PS2; REGULATOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ARNT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER THERAPY; CELL STRAIN MCF 7; DIMERIZATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; ANOXIA; BREAST NEOPLASMS; GENE DELETION; GENE THERAPY; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, ESTROGEN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33846228762     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp0600438     Document Type: Article

References (52)

1. Petrulis, J. R.; Perdew, G. H. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. Biol. Interact. 2002, 141, 25-40.
2. 32P-labelled protein probes using a modified thioredoxin fusion protein expression system in Escherichia coli. Biomol. Eng. 2003, 20, 1-5.
3. 2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J. Appl. Physiol. 2004, 96, 1173-1177.
4. Liu, Y.; Cox, S. R.; Morita, T.; Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 1995, 77, 638-643.
5. Forsythe, J. A.; Jiang, B. H.; Iyer, N. V.; Agani, F.; Leung, S. W.; Koos, R. D.; Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16, 4604-4613.
6. Kietzmann, T.; Roth, U.; Jungermann, K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999, 94, 4177-4185.
7. Semenza, G. L.; Roth, P. H.; Fang, H. M.; Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269, 23757-23763.
8. Firth, J. D.; Ebert, B. L.; Ratcliffe, P. J. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J. Biol. Chem. 1995, 270, 21021-21027.
9. Semenza, G. L.; Jiang, B. H.; Leung, S. W.; Passantino, R.; Concordet, J. P.; Maire, P.; Giallongo, A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271, 32529-32537.
10. Graven, K. K.; Yu, Q.; Pan, D.; Roncarati, J. S.; Farber, H. W. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim. Biophys. Acta 1999, 1447, 208-218.
11. Goss, P. E.; Ingle, J. N.; Martino, S.; Robert, N. J.; Muss, H. B.; Piccart, M. J.; Castiglione, M.; Tu, D.; Shepherd, L. E.; Pritchard, K. I.; Livingston, R. B.; Davidson, N. E.; Norton, L.; Perez, E. A.; Abrams, J. S.; Therasse, P.; Palmer, M. J.; Pater, J. L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349, 1793-1802.
12. Ganz, P. A. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am. J. Med. 2005, 118, 136-141.
13. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8, 562-67.
14. Hudson, C. C.; Liu, M.; Chiang, G. G.; Otterness, D. M.; Loomis, D. C.; Kaper, F.; Giaccia, A. J.; Abraham, R. T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22, 7004-7014.
15. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-S61.
16. Mabjeesh, N. J.; Post, D. E.; Willard, M. T.; Kaur, B.; Van Meir, E. G.; Simons, J. W.; Zhong, H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002 62, 2478-2482.
17. Escuin, D.; Kline, E. R.; Giannakakou, P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005, 65, 9021-9028.
18. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R. H.; Melillo, G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004, 64, 1475-1482.
19. Tan, C.; de Noronha, R. G.; Roecker, A. J.; Pyrzynska, B.; Khwaja, F.; Zhang, Z.; Zhang, H.; Teng, Q.; Nicholson, A. C.; Giannakakou, P.; Zhou, W.; Olson, J. J.; Pereira, M. M.; Nicolaou, K. C.; Van Meir, E. G. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005, 65, 605-612.
20. Kong, D.; Park, E. J.; Stephen, A. G.; Calvani, M.; Cardellina, J. H.; Monks, A.; Fisher, R. J.; Shoemaker, R. H.; Melillo, G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005, 65, 9047-9055.
21. Brown, J. M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999, 59, 5863-5870.
22. Le, Q. T.; Taira, A.; Budenz, S.; Jo Dorie, M.; Goffinet, D. R.; Fee, W. E.; Goode, R.; Bloch, D.; Koong, A.; Martin Brown, J.; Pinto, H. A. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer 2006, 106, 1940-1949.
23. Ohtake, F.; Takeyama, K.; Matsumoto, T.; Kitagawa, H.; Yamamoto, Y.; Nohara, K.; Tohyama, C.; Krust, A.; Mimura, J.; Chambon, P.; Yanagisawa, J.; Fujii-Kuriyama, Y.; Kato, S. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003, 423, 545-550.
24. Klinge, C. M.; Kaur, K.; Swanson, H. I. The aryl hydrocarbon receptor interacts with estrogen receptor alpha and orphan receptors COUP-TFI and ERRalpha1. Arch. Biochem. Biophys. 2000, 373, 163-174.
25. Beischlag, T. V.; Perdew, G. H. ERalpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J. Biol. Chem. 2005, 280, 21607-21611.
26. Safe, S. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol. Lett. 2001, 120, 1-7.
27. Gillesby, B. E.; Stanostefano, M.; Porter, W.; Safe, S.; Wu, Z. F.; Zacharewski, T. R. Identification of a motif within the 5′ regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. Biochemistry 1997, 36, 6080-6089.
28. Wang, F.; Hoivik, D.; Pollenz, R.; Safe, S. Functional and physical interactions between the estrogen receptor Sp1 and nuclear aryl hydrocarbon receptor complexes. Nucleic Acids Res. 1998, 26, 3044-3052.
29. Brunnberg, S.; Pettersson, K.; Rydin, E.; Matthews, J.; Hanberg, A.; Pongratz, I. The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6517-6522.
30. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402-408.
31. Birner, P.; Schindl, M.; Obermair, A.; Plank, C.; Breitenecker, G.; Oberhuber, G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60, 4693-4696.
32. Schindl, M.; Schoppmann, S. F.; Samonigg, H.; Hausmaninger, H.; Kwasny, W.; Gnant, M.; Jakesz, R.; Kubista, E.; Birner, P.; Oberhuber, G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 2002, 8, 1831-1837.
33. Zhong, H.; De Marzo, A. M.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G. L.; Simons, J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59, 5830-5835.
34. Mazure, N. M.; Brahimi-Horn, M. C.; Berta, M. A.; Benizri, E.; Bilton, R. L.; Dayan, F.; Ginouves, A.; Berra, E.; Pouyssegur, J. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem. Pharmacol. 2004, 68, 971-980.
35. Hewitson, K. S.; Schofield, C. J. The HIF pathway as a therapeutic target. Drug Discovery Today 2004, 9, 704-711.
36. Gassmann, M.; Kvietikova, I.; Rolfs, A.; Wenger, R. H. Oxygen- and dioxin- regulated gene expression in mouse hepatoma cells. Kidney Int. 1997, 51, 567-574.
37. Chan, W. K.; Yao, G.; Gu, Y. Z.; Bradfield, C. A. Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation. J. Biol. Chem. 1999, 274, 12115-12123.
38. Pollenz, R. S.; Davarinos, N. A.; Shearer, T. P. Analysis of aryl hydrocarbon receptor-mediated signaling during physiological hypoxia reveals lack of competition for the aryl hydrocarbon nuclear translocator transcription factor. Mol. Pharmacol. 1999, 56, 1127-1137.
39. Nie, M.; Blankenship, A. L.; Giesy, J. P. Interactions between aryl hydrocarbon receptor (AhR) and hypoxia signaling pathways. Environ. Toxicol. Pharmacol. 2001, 10, 17-27.
40. Prasch, A. L.; Andreasen, E. A.; Peterson, R. E.; Heideman, W. Interactions between 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and hypoxia signaling pathways in zebrafish: hypoxia decreases responses to TCDD in zebrafish embryos. Toxicol. Sci. 2004, 78, 68-77.
41. Wood, S. M.; Gleadle, J. M.; Pugh, C. W.; Hankinson, O.; Ratcliffe, P. J. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J. Biol. Chem. 1996, 271, 15117-15123.
42. Ko, H. P.; Okino, S. T.; Ma, Q.; Whitlock, J. P., Jr. Dioxin-induced CYP1A1 transcription in vivo: the aromatic hydrocarbon receptor mediates transactivation, enhancer-promoter communication, and changes in chromatin structure. Mol. Cell. Biol. 1996, 16, 430-436.
43. Watson, P. H.; Pon, R. T.; Shiu, R. P. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 1991, 51, 3996-4000.
44. Rae, J. M.; Johnson, M. D.; Scheys, J. O.; Cordero, K. E.; Larios, J. M.; Lippman, M. E. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res. Treat. 2005, 92, 141-149.
45. Abdelrahim, M.; Smith III, R.; Safe, S. Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah- responsiveness in MCF-7 and HepG2 cancer cells. Mol. Pharmacol. 2003, 63, 1373-1381.
46. Murray, T. J.; Yang, X.; Sherr, D. H. Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A. Breast Cancer Res. 2006, 8, R17.
47. Brown, L. M.; Cowen, R. L.; Debray, C.; Eustace, A.; Erler, J. T.; Sheppard, F. C.; Parker, C. A.; Stratford, I. J.; Williams, K. J. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol. Pharmacol. 2006, 69, 411-418.
48. Harada, H.; Hiraoka, M.; Kizaka-Kondoh, S. Antitumor effect of TAT-oxygen- dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. 2002, 62, 2013-2018.
49. Harada, H.; Kizaka-Kondoh, S.; Hiraoka, M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 2006, 13, 16-26.
50. Yang, L.; Mashima, T.; Sato, S.; Mochizuki, M.; Sakamoto, H.; Yamori, T.; Oh-Hara, T.; Tsuruo, T. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 2003, 63, 831-837.
51. Datta, K.; Sundberg, C.; Karumanchi, S. A.; Mukhopadhyay, D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. 2001, 61, 1768-1775.
52. Harbour, J. W.; Worley, L.; Ma, D.; Cohen, M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol. 2002, 120, 1341-1346.